CytoReason vs Project M
CytoReason vs Project M, compared side by side on 15 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: CytoReason is on 68/100 and Project M on 55/100.
Where each one leads
CytoReason
- our overall score: 68/100 against 55/100
- headcount: 116 against 7
- funding raised: $128M against $10.0M
- LinkedIn following: 12,830 against 295
Project M
- headcount growth: +77.1% against +13.7%
At a glance
| Measure | CytoReason | Project M |
|---|---|---|
| What it is | Develops a computational model of the human body for drug discovery and development. | Leveraging digital twins for real-time, individualized in-patient treatment optimization. |
| Category | Healthcare, Drug Discovery, Clinical Development, Biomarkers | Healthcare, Digital Twin, Clinical Development, Digital Twin Healthcare |
| Sells toBusiness model | B2B | B2B |
| Offering | Software | Software |
| Founded | 2016 | 2023 |
| Headquarters | Tel Aviv, Israel | Tel Aviv, Israel |
| Status | Active | Inactive |
Size, funding and growth
| Measure | CytoReason | Project M |
|---|---|---|
| Employees | 116 | 7 |
| Headcount growthLast 12 months | +13.7% | +77.1% |
| Total funding | $128M | $10.0M |
| Latest round | Series B | Bootstrapped |
| LinkedIn followers | 12,830 | 295 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | CytoReason | Project M |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 68/100 | 55/100 |
| Traction | 60/100 | 11/100 |
| Team | 70/100 | Not published |
| Search visibility | 30/100 | 44/100 |
| Quality | 78/100 | Not published |
| Agent readinessHow well an AI agent can read and act on the site | F (21/100) | Not published |
| Domain ratingLink authority, 0-100 | 40/100 | Not published |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | CytoReason | Project M |
|---|---|---|
| Analytics | Segment | Not detected |
CytoReason vs Project M: common questions
Which is better, CytoReason or Project M?
On our 0-100 score CytoReason rates higher (68/100 against 55/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 15 data points above: read the rows that match what you are buying for.
How do CytoReason and Project M compare on the numbers?
CytoReason leads on our overall score (68/100 against 55/100), headcount (116 against 7), funding raised ($128M against $10.0M), LinkedIn following (12,830 against 295). Project M leads on headcount growth (+77.1% against +13.7%).
Read the full CytoReason review and pricing or the Project M review and pricing. You can also browse other CytoReason alternatives we track.